Loading
companiesCompany
JW Therapeutics
JW Therapeutics, a Juno and WuXi AppTec joint venture, made relma-cel, the first CAR-T developed and manufactured in China to be approved.
Also called: 药明巨诺JW (Cayman) Therapeutics
Overview
Relmacabtagene autoleucel (Carteyva) approved 2021 for large B-cell lymphoma and 2022 for follicular lymphoma; pipeline in mantle cell lymphoma, leukaemia and autoimmune disease. Its commercial struggle (list price around CN¥ 1.29 million, not NRDL-listed, provincial supplementary insurance filling some of the gap) is the case study for how China pays for cell therapy.
Headquarters
Shanghai, CN
Scorecard
All companies#272of 1244 companies, score 17
- approved products +6
- targets +2
- modalities +2
- regions +1
- registry trials +6
1 approved, 0 in phase 3, 0 earlier, 1 targets, 10 registry studies. Formula on the scorecards page.
Type
Cell therapy · 2126.HK
Stage
Public
Website
Founded
2016
ApprovedCell therapy (autologous CD19 CAR-T, 4-1BB)
Relmacabtagene autoleucel · Carteyva
Relma-cel was the first CAR-T therapy developed and made in China to be approved, for large B-cell lymphoma that has come back after two treatments.
Similar pages
- CompanyWuXi Biologics
Shares Ge Li, WuXi AppTec and the tag china.
- CompanyIASO Biotherapeutics
Shares CAR-T cell therapy and the tag china.
- TrialLUMMICAR STUDY 1
Shares CAR-T cell therapy and the tag china.
- InstitutionRenji Hospital, Shanghai Jiao Tong University
Shares CAR-T cell therapy and the tag china.
- InstitutionInstitute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences
Shares CAR-T cell therapy and the tag china.
- InstitutionPeking University People's Hospital
Shares CAR-T cell therapy and the tag china.
- CompanyJuventas Cell Therapy
Shares CAR-T cell therapy and the tag china.
- TrialFUMANBA-1
Shares CAR-T cell therapy and the tag china.
fronts
technologies
drugs
ApprovedCell therapy (autologous CD19 CAR-T, 4-1BB)
Relmacabtagene autoleucel · Carteyva